The state of California currently has 945 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Focal Therapy for Localized Prostate Cancer
NCT06270043
Recruiting
This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: University of California, San Diego, La Jolla, California
Conditions: Prostate Cancer
Register for Updates
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580
Recruiting
This is a randomized controlled trial to compare survival for patients who undergi robotic assisted laparoscopy versus open radical hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: University of California San Diego Medical Center, Encinitas, California +8 locations
Conditions: Cervical Cancer
Register for Updates
Study Assessing QBS72S For Treating Brain Metastases
NCT05305365
Recruiting
This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic breast cancer with CNS involvement.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: Stanford Cancer Institute, Palo Alto, California
Conditions: Brain Metastases, Breast Cancer
Register for Updates
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985
Recruiting
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: UC Irvine/Chao Family Comprehensive Cancer Center, Orange, California +1 locations
Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Register for Updates
GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer
NCT05415007
Recruiting
The purpose of this study is to examine a psychotherapeutic and psycho-educational intervention offered in virtual settings to caregivers of youth with cancer. Human subjects must be used because they are the object of the intervention.
Gender:
All
Ages:
Between 8 years and 18 years
Trial Updated:
02/21/2024
Locations: Stanford Cancer Institute, San Francisco, California
Conditions: Cancer
Register for Updates
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
NCT00373347
Recruiting
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Liver Cancer
Register for Updates
Advanced Gastrointestinal Endoscopic Imaging
NCT01034670
Recruiting
To develop new methods to detect malignant and premalignant conditions of the gastrointestinal tract.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Gastrointestinal Diseases, Gastric (Stomach) Cancer, Gastrointestinal Stromal Tumor (GIST)
Register for Updates
A Culturally Sensitive Social Support Intervention
NCT02946697
Recruiting
This study is a randomized controlled trial (RCT) to assess the impact of a culturally based social support program (i.e. Joy Luck Academy, JLA) among Chinese American breast cancer survivors.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Herald Cancer Association, Los Angeles, California
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
NCT03809624
Recruiting
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination with Pembrolizumab. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides localized conditional T-cell co-stimulation through 4-1BB agonism.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: City of Hope at Irvine Lennar, Duarte, California +3 locations
Conditions: Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: City of Hope, Duarte, California +2 locations
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT04768426
Recruiting
The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes in ctDNA in the blood over time received during capecitabine treatment. Results of ctDNA analysis will be correlated to genetic characteristics of individual tumors. This may inform future clinical tria... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Stanford University, Stanford, California
Conditions: Triple Negative Breast Cancer, Breast Cancer
Register for Updates
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378
Recruiting
This study will evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PDy) of novel immunotherapy combinations compared with immunotherapy monotherapy in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] ≥ 50%), previously untreated, unresectable, locally advanced or metastatic NSCLC. Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the documen... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: GSK Investigational Site, Los Angeles, California
Conditions: Lung Cancer, Non-Small Cell
Register for Updates